• PDF: Delivered by email usually within 24 to 48 UK business hours.

Pharmaceuticals

Pharmaceuticals

The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report provides a bird's eye view of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as, patent expiry of blockbuster global drugs, rising demand for old age related medications and cardiovascular drugs, and the rise of biogenerics, among others. A briefly summarized outlook presents unequivocal views on the industry's future. Punctuated with 18 statistically rich tables, the global market discussion offers special preludes to major market segments, such as, Prescription Drugs, Blockbuster Drugs, Anti-Depressants, COPD, Cholesterol Drugs, CNS Drugs, Cardiovascular Drugs, Cancer Drugs, Attention Deficit Hyperactive Disorder, Artherosclerosis, Asthma, Anti-Infective Prescription Agents, Receptor Blockers, Psychotic Disorders, Osteoporosis, Multiple Sclerosis, Irritable Bowel Syndrome, Insomnia, Immunosupression Hypertension, Epilepsy, Rhinitis, Urinary Disorders, HIV/AIDS, and Diabetes among others. Also included is a recapitulation of recent mergers, acquisitions, and other noteworthy strategic corporate developments. Annotated with quantitative analysis and research findings, the discussion on the US market contains 46 market data tables designed to give the reader a macro level understanding of the market. Other regional markets covered include Canada, Japan, Western Europe, Switzerland, UK, China, India, Korea, Malaysia, and Brazil. The purpose of the abstracted regional market discussion is to provide the reader an introduction to these markets. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 3,083 companies worldwide.

  • 1.Overview
    • US Leads the Pharmaceuticals Sector
    • Global Trends in Pharmaceutical Industry
    • Aging World Population Drives Up Demand for Pharmaceuticals
    • Market Booming for Old Age Related Medications
    • BRIC Countries to Drive Up the Pharmaceuticals Sector
    • China and India Emerge as Major Contract Manufacturing Hubs
    • Rising Consumer Health Consciousness Drives Up the OTC Drugs Sector
    • Market Growing for OTC Scar Management Solutions
    • Market Growing for Artificial Tears
    • Faster Drug Approval Process, the Need of the Hour
    • Cardiovascular Drugs Still Rules the Roost
    • Global Analgesics Market to Soar
    • Market Growing for Antidepressants
    • New R&D Initiatives To Spark Up Growth
    • Acquisitions and Mergers Propels the Pharmaceuticals Sector
    • Generics Expand Share
    • Global Patent Expiries of Select Major Drugs: 2007-2012
    • Major Generic Drugs
    • Leading Generic Drug Companies
    • Generic Competition Provides the Necessary Momentum
    • Authorized Generics - A Major Concern for Generic Makers
    • Regulatory Reform Drive the European Market
    • New Areas of Expertise
    • Biogeneric Revolution
    • Bio-generics to Exhibit Slow Start
    • Biogeneric Market Trends Worldwide: 2005-2010
    • Select Global Biotech Drugs Off-Patent: 2001-2006
    • Potentially Key Competitors in the Biogenerics Space: 2005-2010
    • Product Lifecycle Management - The Deciding Factor
    • Packaging Trends
    • Blister Packaging to Record High Growth
    • Outlook
    • Pharmacogenomics to Substitute Pharma's Business Model
    • Biopharmaceuticals - The Next Generation
    • Nano-Enabled Drug Discovery Geared to Lead
    • Proteomics - The Current Spotlight
    • Neurodegeneration Treatments Identified in Research
  • 2.Major Class of Drugs
    • Antidepressants
    • Antiepileptics
    • Antipsychotics
    • Antirheumatic Non-steroidals
    • Antulcerants
    • Calcium Antagonists
    • Erythropoietins
    • Oral Antibiotics
    • Lipid Regulators
    • Antiarthritics
    • Antihistamines
    • Antihyperlipidemics
    • Oral Antidiabetics
  • 3.Geographical Landscape
    • Leading Global Pharmaceutical Players
  • 4.Mergers and Acquisitions
  • 5.Strategic Corporate Developments
  • 6.Product Launches
  • 7.Review of Select Segments
    • Prescription Drugs
    • Market Overview
    • Blockbuster Drugs
    • Market Overview
    • Antidepressants
    • Market Overview
    • Leading Antidepressants Worldwide and Year of Patent Expiry
    • Chronic Obstructive Pulmonary Disease
    • Market Overview
    • Cholesterol Drugs
    • Market Overview
    • Leading Cholesterol Drugs Worldwide and Year of Patent Expiry
    • CNS Drugs
    • Market Overview
    • Cardiovascular Drugs
    • Market Overview
    • Leading Cardiovascular Prescription Drugs
    • Cancer Drugs
    • Market Overview
    • Attention Deficit Hyperactive Disorder
    • Market Overview
    • Artherosclerosis
    • Market Overview
    • Asthma
    • Market Overview
    • Leading Brands
    • Asthma Drug Sales by Respiratory Category
    • Antinfective Prescription Agents
    • Market Overview
    • Receptor Blockers
    • Market Overview
    • Psychotic Disorders
    • Market Overview
    • Worldwide Leading Prescription Drugs for Psychotic Disorders and Year of Patent Expiry
    • Osteoporosis
    • Market Overview
    • Multiple Sclerosis
    • Market Overview
    • Irritable Bowel Syndrome
    • Market Overview
    • Insomnia
    • Market Overview
    • Immunosuppression
    • Market Overview
    • Hypertension
    • Market Overview
    • Epilepsy
    • Market Overview
    • Leading Prescription Drugs for Epilepsy and Year of Patent Expiry
    • Rhinitis
    • Market Overview
    • Urinary Disorders
    • Market Overview
    • HIV/AIDS
    • Market Overview
    • FDA Sanctions Fast Track Status to First-in-Class HIV Drug
    • Diabetes
  • 8.United States
    • Lower Margins in the US leads to Consolidation and Diversification in the Global Market
    • Beset with Setbacks
    • Regulations Shaping the US Pharmaceutical Industry
    • Medicare Drug Improvement and Modernization Act (MMA)
    • The American Jobs Creation Act of 2004
    • Autonomous Panel for Screening Drug Safety
    • GPhA Drives FDA to Back Generic Drugs
    • Rapid Surge in ANDAs
    • Competitive Scenario
    • Pharmaceuticals Market by Therapeutic Category
    • Leading Drugs
    • Consumer Healthcare
    • Packaging
    • Leading Distribution Channels
    • Promotional Expenditure
    • External Analgesics
    • Internal Analgesics
    • Cancer Therapeutics
    • Generic Drugs
    • Market Highlights
    • Leading Generic Manufacturers
    • Leading Drugs by Value Sales
    • Authorized Generics
    • Diabetes
    • Oral Diabetes Drugs
    • Key Players
  • 9.Canada
    • Market Overview
    • Amendments to Canadian Drug Patent Laws
    • New Regulations Provide Accurate Timeline for Introduction of Generics
    • 10.Japan
      • Market Overview
      • Trends in Oncology Market
    • 11.Europe
      • Market Overview
      • Investments in R & D
      • Generic Drugs
    • 11a. Western Europe
      • Market Overview
      • Export Scenario
      • Research and Development Expenditure
      • Generic Drugs
    • 11b. Switzerland
      • Market Overview
  • 11c. United Kingdom
    • Market Overview
    • Over-The-Counter Medications
    • Analgesics
    • Oral Analgesics
    • Statin Drugs
    • 12.Asia/Asia-Pacific
      • Market Overview
      • Generic Market - A Perspective
    • 12a. China
      • Trends
      • Demographics Encourage Growth
      • Stringent Guidelines and Standards to BoostQuality
      • OTC Drugs Leads the Profit Traditional Chinese Medicine to Prosper
      • Boom Time for Chinese API Suppliers
      • Consolidation to Strengthen the Industry
      • Overview
      • Outlook
    • 12b. India
      • Market Overview
      • Too Fragmented Industry
      • Hot Destination for Foreign Players
      • Indian Pharmaceutical Industry to Surge
      • Contract Research to Develop Indian Pharma Industry
      • India Vies for Big Share in Pharmaceutical Outsourcing
      • Noteworthy Foreign Investments in India's Pharma Market in the Past
      • Indian Acquisitions of Foreign Operations in the Past
      • Select Indo-US Strategic Partnerships and Alliances
      • Indo-US Synergies in Pharmaceuticals
      • Contract manufacturing by Indian Companies Expected to Rise Exponentially - Select Recent Strategic Alliances
      • Indian Pharma - A SWOT Analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
      • Indian Pharma Sector (pre- and post- patent reform)
      • New Opportunities and Challenges for the US Players
      • Growing Presence of Indian Players in Europe
      • Promoting Factors
      • Therapeutic Areas
      • Growth Strategies
      • Surfacing Trends - Generic Drugs
      • Pharma Outsourcing
      • TRIPS and Pharmaceuticals
      • Leading Pharmaceutical Companies
    • 12c. Korea
      • Market Overview
  • 13.Malaysia
    • Industry Overview
    • Enhancement of Pharmaceuticals
    • 14.Latin America
    • 14a. Brazil
      • Governing Facts
      • Initiatives
      • Market Scenario
      • Generic Drugs
  • Global Directory
  • List of Tables
    • Table 1: Global Pharmaceutical Market (2006): Sales in US$ Billion by Region - US, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa and Canada
    • Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2006 (In %)
    • Table 3: Global Generic Drugs Market by Geographic Region: Annual Sales Estimates in US$ Million for 2003 through 2008 for USA, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World
    • Table 4: Global Generic Drugs Market (2005 & 2006): Percentage Breakdown of Value Sales by Therapeutic Category - Cardiovascular, Anti-Infective, Analgesic, Central Nervous System (CNS), Gastrointestinal, Cancer, Respiratory & Anti-Allergic, and Others
    • Table 5: Leading Generic Drugs Worldwide by Retail Sales (2005): Hydrocodone/APAP, Gabapentin, Amoxicillin/pot. clav., Paroxetine, Oxycodone, Lisinopril, Metformin, Omeprazole, Fentanyl transdermal, Amoxicillin, Fluoxetine, Oxycodone w/ APAP, Albuterol aerosol, Lovastatin, Levothyroxine, Lorazepam, Atenolol, Alprazolam, Cephalexin, and Warfarin
    • Table 6: Leading Generic Drugs Worldwide by Total Units Dispensed (2005): Annual Estimates in Millions for Hydrocodone/APAP, Amoxicillin, Peg 3350/electrolyte, Metformin, Alprazolam, Lisinopril, Atenolol, Hydrochlorothiazide, Furosemide Oral, Chlorhexidine Gluconate, Gabapentin, Ibuprofen, Levothyroxine, Metoprololtartrate, Albuterol nebulizer solution, Propoxyphene-N/APAP, Potassium chloride, Cephalexin, Amoxicillin/pot. Clav., and Tramadol
    • Table 7: Leading Companies in the Global Generic Drugs Market (2005): Percentage Breakdown by Value Sales for Sandoz, Teva Pharmaceutical Industries, Merck Generics, Actavis, Ratiopharm, Mylan Laboratories, IVAX, Barr Pharmaceuticals, Ranbaxy Laboratories, and Others
    • Table 8: Leading Companies in the Global Generics Pharmaceutical Market by Number of Prescriptions Dispensed (2005): Annual Estimates in Millions for Teva/Ivax, Mylan, Sandoz, Watson, Mallinckrodt, Alpharma, Qualitest, Par, Barr, Laboratories, and URL/Mutual
    • Table 9: TOP 10 Pharmaceutical Products Worldwide in 2004
    • Table 10: Global Pharmaceutical Packaging Demand by Country: Percentage Market Share for 2005, 2008, and 2010 for Europe, North America, Latin America, and Others
    • Table 11: Global Demand for Biopharmaceuticals: Annual Market Estimates for 2004 through 2010 in Millions of Liters
    • Table 12: Leading Companies in the Global Pharmaceutical Market by Healthcare Research and Development (R&D) Spending (2005): Annual Estimates in US$ Million for Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc, Sanofi-Aventis Group, Novartis, Roche, Merck & Co., AstraZeneca Plc, Eli Lilly and Co., Wyeth, Bristol-Myers Squibb Co., Amgen Inc., Schering-Plough Corp., Abbott Laboratories, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Co., Daiichi Sankyo Co., Genentech Inc., Schering AG, and Astellas Pharma Inc.
    • Table 13: Global Pharmaceutical Market by Region/Country (2005): Annual Sales in US$ Billion for United States, Europe, Japan, Asia-Pacific, Latin America, Middle East/Africa, and Canada
    • Table 14: Global Pharmaceutical Market by Region/Country (2005): Percentage Breakdown of Value Sales for United States, Europe, Japan, Asia Pacific, Latin America, Middle East/Africa, and Canada
    • Table 15: Leading Global Pharmaceutical Companies by Revenue (2006): Annual Estimates in US$ Billion for Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, Johnson & Johnson, AstraZeneca, Merck, Roche, Abbott, and Amgen
    • Table 16: Leading Global Pharmaceutical Companies by Net Income (2005): Annual Estimates in US$ Million for Johnson & Johnson, GlaxoSmithKline Plc, Procter & Gamble Co., Pfizer Inc., Novartis, Roche, AstraZeneca Plc., Merck & Co., Amgen Inc., Wyeth, Abbott Laboratories, Bristol-Myers Squibb Co., Sanofi-Aventis Group, Takeda Pharmaceutical Co., and Bayer
    • Table 17: Leading Global Pharmaceutical Companies by Market Capitalization (2006): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Johnson & Johnson, GlaxoSmithKline Plc., Novartis, Sanofi-Aventis Group, AstraZeneca Plc, Merck & Co., Genentech Inc., Amgen Inc., Abbott Laboratories, Wyeth, Eli Lilly and Co., Bristol-Myers Squibb Co., and Bayer
    • Table 18: Leading Global Pharmaceutical Companies by Shareholders' Equity (2005): Annual Estimates in US$ Million for Pfizer Inc., Procter & Gamble Co., Sanofi- Aventis Group, Johnson & Johnson, Roche, Novartis, Amgen Inc., Takeda Pharmaceutical Co, Merck & Co., Abbott Laboratories, Bayer, AstraZeneca Plc., GlaxoSmithKline Plc., Wyeth, and Bristol-Myers Squibb Co.
    • Table 19: Leading Global Pharmaceutical Companies by Aggregate Assets (2005): Annual Estimates in US$ Million for Procter & Gamble Co., Pfizer Inc., Sanofi-Aventis Group, Johnson & Johnson, Novartis, Roche, GlaxoSmithKline Plc., Bayer, Merck & Co., Wyeth, Amgen Inc., Abbott Laboratories, Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., and AstraZeneca Plc
    • Table 20: Leading Global Pharmaceutical Companies by Number of US-dispensed Prescriptions (2005): Annual Estimates in Millions for Pfizer, Novartis, Teva, Mylan Laboratories, Watson, GlaxoSmithKline, Merck & Company, Ivax Corporation, AstraZeneca, Mallinckrodt, Johnson & Johnson, Sanofi-Aventis, Barr Laboratories, Abbott Laboratories, and Alpharma USPD
    • Table 21: Leading Global Pharmaceutical Companies by Direct-to-consumer Advertisement Spending (2005): Annual Estimates in US$'000 for GlaxoSmithKline, Pfizer, AstraZeneca, Sanofi-Aventis, Merck & Co., Johnson & Johnson, Novartis, Sepracor, Merck/Schering-Plough Pharmaceuticals, Amgen, Schering-Plough, Allergan, Lilly Icos, Abbott Laboratories, Wyeth, Eli Lilly, Roche, Procter & Gamble, Tap Pharmaceutical Products, and Astellas Pharma
    • Table 22: Global Leading Prescription Drug Brand Sales by Category: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Cardiovascular, Hypertension Drugs, Anti-Infective, Psychotherapeutic Agents, Gastrointestinal Therapies, Respiratory Products, and Cholesterol Reduction.
    • Table 23: Global Leading Prescription Drugs Sales by Therapeutic Category (Blood Modifiers): Annual Market Estimation for 2003 through 2008 in Millions of US$ for Anemia, Deep Vein Thrombosis, Hemophilia, Occlusive Arterial Disease, Pulmonary Embolism, Leukopenia, Iron Intoxication, White Blood Cell Enhancement and Peripheral Disease.
    • Table 24: Global Drugs Gaining Blockbuster Status by Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Advair/Seretide, Nexium, Plavix, Singulair, Mabthera/Rituxan, Lovenox/ Clexane, Ambien/Stilnox, Wellbutrin, and Others
    • Table 25: Global Top-Selling Drugs Value Sales: Annual Market Estimates for 2003 through 2008 in Billions of US$ for Chiral, Racemic, and Achiral Drugs
    • Table 26: Global Chronic Obstructive Pulmonary Disease Drug Sales by Leading Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Beta2-agonists, Anticholinergics, Corticosteroids, Methyl Xanthines and Leukotinene Antagonists
    • Table 27: Global Leading Central Nervous System Prescription Drugs Sales by Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Depression, Psychotic disorders, Epilepsy, Migraine, Insomnia, Anesthesia, Anxiety, Alzheimer disease, Attention deficit hyperactivity disorder, and Dystonia
    • Table 28: Global Asthma Drug Value Sales by Respiratory Category: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Inhaled Corticosteroids, Short Acting Beta Agonists, Long Acting Beta Agonists, Combinations, Anti-Leukotrienes and Other Asthma Therapeutics
    • Table 29: Global Leading AntInfective Prescription Agents Sales for Various Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Bacterial Infections, Viral Infections and Fungal Infections
    • Table 30: Receptor Blockers Value Sales in the Global Market: Annual Market Estimates for 2003 through 2008 in Billions of US$
    • Table 31: Global Sales of Leading Prescription Drugs for Multiple Sclerosis in Millions of US$:) 2005
    • Table 32: Global Leading Prescription Drug Sales for Multiple Sclerosis: Annual Market Estimates for 2003 through 2008 in Millions of US$
    • Table 33: Global Leading Drug Value Sales by Category for Treating Irritable Bowel Syndrome: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Laxatives, Antidiarrheals, and Antidepressants
    • Table 34: Global Leading Drug Value Sales by Category for Treating Irritable Bowel Syndrome: Percentage Market Share for 2004 and 2008 for Laxatives, Antidiarrheals, and Antideoressants
    • Table 35: Global Leading Prescription Drugs for Immunosuppression by Sales: Annual Market Estimates for 2003 through 2005 in Millions of US$ for Neoral/ Sandimmun, Cellcept, Prograf and Medrol
    • Table 36: Global Value Sales of Leading Prescription Drugs for Hypertension: 2004 and 2005 in Millions of US$ for Norvasc (Pfizer), Diovan/Co-Diovan (Novartis), Cozaar and Hyzaar (Merck & Co.), Prinivil and Prinzide (Merck & Co.), Lotensin/Cibacen and Lotrel (Novartis), Toprol-XL/Seloken (AstraZeneca), Tritace/Delix, Blopress (Takeda Chemical Industries), Zestril (AstraZeneca), Vasotec and Vaseretic (Merck & Co.), and Accupril and Accuretic (Pfizer)
    • Table 37: Global Leading Prescription Drugs Sales for Urinary Disorders by Symptoms: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Benign Prostatic Hypertrophy and Overactive Bladder
    • Table 38: Global Sales of Medications for Diabetes by Segment: Percentage Market Share for 2005, 2008, and 2010 for Oral Ant Diabetic Drugs, and Insulin Products
    • Table 39: Global Sales of Medications for Diabetes by Segment: Annual Market Estimates for 2004 through 2010 in Billions of US$ for Oral Anti Diabetic Drugs, and Insulin Products
    • Table 40: US Drug Market (2006): Chain Drug Stores Sales in US$ Billion by Product Category-Total Prescription (Prescription drugs--brand, Prescription drugs--brand, specialty, Prescription drugs--generic), Nonprescription drugs, Health and personal care, General merchandise, DME and HHC and Other
    • Table 41: US Pharmaceutical Market (2006): Percentage Breakdown of Value Sales by Therapic Category- Lipid Lowerers--Statins+ZET, Proton Pump Inhibitors, Anti-Depressants, Antipsychotics, 0TH, Erythropoietins, Seizure Disorders, Antineo Monoclonal Antib, Angiotensin II Antag, Insulin Sensitizer, Calcium Blockers, Antiarth, BIOL RESPMOD, Bisphosphonates, Anti-Platelets, Oral, Immune System Adjuncts, Steroid, Inhaled BronchC, ACE Inhibitors, Non-Barb, 0TH, GI Anti- Inflammatory, Aanaleptics, Immunologic Interferons and Others
    • Table 42: US Pharmaceutical Market (2006): Sales In US$ Million for Major Distributors- McKesson Pharmaceutical Solutions, Cardinal Health, AmerisourceBergenDrug, Kinray and HD Smith Wholesale Drug
    • Table 43: Leading Pharmaceutical Companies in the US by Branded Drug Sales (2006): Annual Estimates in US$ Million for GlaxoSmithKline, Abbott, Forest, Monarch, Dey Laboratories, Bausch & Lomb, Ivax Laboratories, Roxane, Taro USA, Par, Mylan, Repacker, Bertek, Alpharma US, Mallinkrodt, Xanodyne, Pharmaderm, Morton Grove, Dava, and Lupin
    • Table 44: Leading Pharmaceutical Companies in the US by Total Drug Sales (2006): Annual Estimates in US$ Million for GlaxoSmithKline, Teva USA, Abbott, Mylan, Sandoz, Watson Laboratories, Forest, Par, Barr, Ivax, Greenstone, Monarch, Mallinkrodt, Ranbaxy, Apotex, Eon Laboratories, Qualitest, Endo Generic, Pliva, and Danbury
    • Table 45: Leading Vendors in the US Athlete's Foot/foot Care Medication Market (2006): Sales through Drugstores in US$' 000 for Schering-Plough, Novartis Consumer Health, NDC Laboratories, Combe, Miracle of Aloe, Taro Pharmaceuticals, Chattem, Del Laboratories, Eulactol USA, and Alva/Amco
    • Table 46: Leading Vendors in the US Athlete's Foot/foot Care Medication Market (2006): Sales through Drugstores in '000 Units for Schering-Plough, Novartis Consumer Health, Combe, Chattem, Del Laboratories, Taro Pharmaceuticals, Miracle of Aloe, Eulactoi USA, Pfizer, and NDC Laboratories
    • Table 47: United States Pharmaceuticals Market by Leading Therapeutic Category (2005): Annual Sales in US$ Billion for Statins, Proton Pump Inhibitors, Antipsychotics, Antidepressants, Erythropoietins (cancer), Seizure Disorders, Angiotensin II Antagonists (anti-hypertensives), Calcium blockers, Insulin Sensitizers, and Monoclonal antibodies (cancer)
    • Table 48: United States Pharmaceuticals Market (2005): Percentage Breakdown of Drug Spending by Therapeutic Category - Cardiovascular, CNS: Neurology, Mental Health & Pain, Gastro-enterology, Respiratory & Allergy, Endocrine & Diabetes, Anti-infectives, Rheumatology & Musculoskeletal, and Others
    • Table 49: Leading Branded Drugs in the US Pharmaceuticals Market (2005): US Sales in US$ Billion for Lipitor, Zocor, Nexium, Prevacid, Advair, Plavix, Zoloft, Epogen, Procrit, and Aranesp
    • Table 50: Leading Drug Classes by Prescriptions Volume in the US: Annual Market Estimates for 2003 through 2008 in Millions of Numbers for Codeine & Comb Non-Inj, Ssris / Snris, Cholest Rdcr Statins, Ace Inhib W / O Diuret, Beta-Blockers, O /C Estr / Progest, Calcium Blockers, Thyroid. Synthetic, Antihistamine Cap-Tab, and Proton Pump Inhibitors
    • Table 51: Leading Brands in the US First Aid Ointments/antiseptics Market (2006): Sales through Drugstores in US$'000 for Neosporin Plus, Neosporin, Mederma, Aquaphor, Polysporin, Solarcaine, Hibiclens, Betadine, BD, and Bactine
    • Table 52: Leading Brands in the US First Aid Ointments/antiseptics Market (2006): Sales through Drugstores in '000 Units for Neosporin Plus, Neosporin, BD, Aquaphor, Polysporin, Solarcaine, Mederma, Bactine, Hibiclens, and Bladex
    • Table 53: United States' Leading Cough Syrup Brands (2005): Sales through Drugstores in US$ Million for Robitussin OM, Delsym, Robitussin, Vicks NyQuil Cough, Diabetic Tussin, Zicam, Cough Mist, Vicks Formula 44, Vicks Formula 44e, Robitussin Pediatric, and Robitussin Honey Cough
    • Table 54: United States' Leading Cough Syrup Brands (2005): Sales through Drugstores in Units for Robitussin OM, Robitussin, Delsym, Vicks NyQuil Cough, Vicks Formula 44, Vicks Formula 44e, Diabetic Tussin, Robitussin Pediatric, Robitussin Honey Cough, Zicam Cough Mist
    • Table 55: Leading Brands in the US Ear Drops/treatments Market (2006): Sales through Drugstores in US$ for Similasan, Debrox, Murine, Hyland, Swim Ear, Physicians Choice, Auro Dri, Otix, Auro, and Clear Tinnitus
    • Table 56: Leading Brands in the US Ear Drops/treatments Market (2006): Sales through Drugstores in Units for Similasan, Debrox, Swim Ear, Murine, Auro Dri, Hyland, Physicians Choice, Otix, Auro, and Clear Tinnitus
    • Table 57: United States' Leading Oral Pain Relief Brands (2005): Sales through Drugstores in US$'000 for Orajel, Anbesol, Baby Oraj, Peroxyi, Zilactin, Temparin, Glyoxide, Dentemp, Kank-A, and Hyland's
    • Table 58: United States' Leading Oral Pain Relief Brands (2005): Sales through Drugstores in '000 Units for Orajel, Anbesol, Baby Orajel, Peroxyl, Temparin, Dentemp, Hyland's, Zilactin, Kank-A, and Glyoxide
    • Table 59: Leading Brands in the US Weight Control Candy/Tablet Market (2005): Sales through Drug Stores in US$ Million for Relacore, Cortislim, Zantrex 3, Trim Spa X32, Hydroxycut, Trim Spa, Xenadrine EFX, Metabolife Ultra, Estrin D, and Stacker 2
    • Table 60: Leading Brands in the US Weight Control Candy/Tablet Market (2005): Sales through Drug Stores in Units for Relacore, Trim Spa X32, Cortislim, Zantrex 3, Metabolife Ultra, Hydroxycut, Xenadrine EFX, Stacker 2, Trim Spa, and Estrin D
    • Table 61: United States' Leading Nasal Aspirator Brands (2005): Sales through Drug Stores in US$ for Luv N Care, First Years, Safety 1st, Little Noses, Ross, Gerber, Sunmark, Cara, and Acu Life
    • Table 62: United States' Leading Nasal Aspirator Brands (2005): Sales through Drug Stores in Units for Luv N Care, First Years, Safety 1st, Little Noses, Gerber, Ross, Sunmark, Cara, and Acu Life
    • Table 63: Leading Brands in the US Eye/Lens Care Solutions Market (2006): Sales through Drug Stores, Supermarkets, and Discount Stores (excluding Wal-Mart) in US$ Million for Alcon Opti-Free Express, Bausch & Lomb Renu Multiplus, Amo Complete Moisture Plus, Alcon Systane, Allergan Refresh Tears, Clear Eyes, Alcon Opti-Free Replenish, Ciba Vision Clear Care, Visine Advanced Relief, and Visine
    • Table 64: Leading Brands in the US Eye/Lens Care Solutions Market (2006): Sales through Drug Stores, Supermarkets, and Discount Stores (excluding Wal-Mart) in Million Units for Alcon Opti-Free Express, Bausch & Lomb Renu Multiplus, Clear Eyes, Visine Advanced Relief, Visine, Amo Complete Moisture Plus, Alcon Opti-Free Replenish, Alcon Systane, Ciba Vision Clear Care, and Allergan Refresh Tears
    • Table 65: Pharmaceutical Product Sales by Category through Food, Drug and Mass Merchandise Stores in the US: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Vitamins, Cold/Allergy/Sinus Tablets, Skin Care, Gastrointestinal - Tablets, Weight Control/ Nutrition Liquid/ Powder, First Aid Accessories, Miscellaneous Health Remedies, First Aid Treatment, Cold/Allergy/Sinus Liquids, Gastrointestinal - Liquid and Cough Drops
    • Table 66: Pharmaceutical Industry's Packaging Demand by Type in the US: Annual Market Estimates for 2003 through 2008 in Millions of US$ for Blister Packaging, Plastic Bottles, Secondary Containers and Other Primary Containers
    • Table 67: United States' Pharmaceuticals Market by Retail Outlet (2005): Percentage Breakdown of Value Sales for Traditional Drug Chains, Mail Order/Internet, Independent Drug Stores, Supermarkets, and Mass Merchants
    • Table 68: Prescription Pharmaceutical Sales through Retail/Distribution Channel in the US: Percentage Market Share for 2004 and 2005 for Chains, Indep., Non-Fed Hosp., Mail Order, Food Stores, Clinics, LTC, HMO, Fed. Facilities, and Others
    • Table 69: Leading Pharmacy Chains in the United States (2005): Retail Rx Sales in US$ Million for CVS Corp., Walgreens, Wal-Mart, Rite Aid, Brooks-Eckerd, Kroger, Supervalu, Safeway, Medicine Shoppe, and Sears Holdings
    • Table 70: United States' Pharmaceutical Advertising Expenditure through Medical Journals for 2003 through 2005 (In US$ '000)
    • Table 71: External Analgesics Sales through Distribution Channel in the US: Percentage Market Share for 2004 and 2005 for Mass Merchandise, Food and Drug Stores
    • Table 72: Leading External Analgesics Drug Brand Volume Sales in the US: Percentage Market Share for 2004 and 2005 for Bengay, Joint-Ritis, Icy Hot, Aspercreme, Flex All 454, Mineral Ice, Salonpas, Absorbine Jr., Sportscreme, and Others
    • Table 73: United States' Leading Internal Analgesic Liquid Brands (2005): Sales through Drugstores in US$ Million for Children's Motrin, Tylenol, Children's Tylenol, Infant's Motrin, Children's Advil, Advil, Gel Stat, Tylenol PM, Elixsure, and Motrin
    • Table 74: United States' Leading Internal Analgesic Liquid Brands (2005): Percentage Breakdown of Volume Sales through Drugstores for Children's Motrin, Tylenol, Children's Tylenol, Infant's Motrin, Children's Advil, Advil, Gel Stat, Tylenol PM, Elixsure, and Others
    • Table 75: Number of New Cases of Cancer Reported in the US: 2005 in Thousands for Non-melanoma Skin Cancer, Recurrent Colon Polyps, Prostate Cancer, Superficial Bladder Cancer, Barrett's Esophagus Cancer, and Others
    • Table 76: Top Cancer Incidence Types in the US: 2005 per 100,000 People for Prostate, Breast, Lung, Colon & rectum, and Testis
    • Table 77: United States Market for Generic Drugs by Therapeutic Category: Annual Sales Estimates in US$ Million for 2003 through 2008 for Cardiovascular, Analgesic, Anti-Infective, Central Nervous System (CNS), Gastrointestinal, Respiratory & Anti- Allergic, Cancer and Others
    • Table 78: United States Generic Cardiovascular Drugs Market (2005): Percentage Share Breakdown by Segment - Beta Blockers and ACE Inhibitors; Calcium Channel Blockers; Angina and Arrhythmia Drugs; Diuretics; Vasodilators, Vasopressors, and Anticoagulants
    • Table 79: United States Generic Central Nervous System (CNS) Drugs (2005): Percentage Breakdown by Segment - Sedatives/Hypnotics, Tranquilizers and Antianxiety Agents, Antidepressants, Stimulants, and Antipsychotics, and Anticonvulsants, Antispasmodics and Muscle Relaxants
    • Table 80: United States Generic Gastrointestinal Drugs (2005): Percentage Breakdown by Segment - Anti-Spasmodics Drugs, Anti-Nauseants, Anti-Ulcer, Digestants, and Anti-Diarrheals
    • Table 81: United States Market for Generic Ophthalmic Drugs (2005): Percentage Breakdown by Segment - Glaucoma Drugs, Anti-Infective, and Anti- Inflammatory Drugs and Mast Cell Inhibitors
    • Table 82: Leading Manufacturers in the US Generic Drugs Market (2006): Percentage Breakdown by Prescriptions for Teva, Mylan, Watson, Sandoz, Barr, Mallinckrodt, Actavis, Qualitest, Par, Greenstone and Others
    • Table 83: Leading Players in the US Generic Drugs Market (2005): Percentage Breakdown of Value Sales for Teva, Novartis (Sandoz), Mylan, Watson, Ivax, Par, Pfizer (Greenstone), Actavis, Boehringer Ingelheim, Baxter Healthcare, and Others
    • Table 84: Leading Generic Drug in the US: 2005 Percentage Market Share for Hydrocodone/ APAP, Ranitidine HCI, Albuterol aerosol, Alprazelam, Lorazepam, Atenolol, Propoxyphene- N/APAP, Tamoxifen, Cephalexin, & Others
    • Table 85: United States Generics Market (2003-2005): Growing Share of Authorized Generics in the Total Market
    • Table 86: Canadian Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008
    • Table 87: Share of Generic and Branded Drugs in the Canadian Prescription Drug Market: 2006
    • Table 88: Japanese Pharmaceuticals Market (2005): Percentage Breakdown of Value Sales by Sector - Cardiovascular, Alimentary/ metabolism, Central Nervous System, Respiratory, and Others
    • Table 89: Japanese Pharmaceuticals Market: Percentage Share of Bio-Pharmaceuticals in Total Drug Approvals for 2003, 2005, and 2008
    • Table 90: Oncology Treatment in the Japan: Annual Market Estimates for 2003 through 2008 in Billions of US$
    • Table 91: European Pharmaceutical Market (2006): Sales in US$ Billion by Region- France, Germany, UK, Italy and Rest of Europe
    • Table 92: Natural Ingredients Imports by Product Group in the European Union: 2005 in Millions of Euros for Medicinal and Aromatic Plants, and Others
    • Table 93: European Market for Generic Drugs by Therapeutic Category: Annual Sales Estimates in US$ Million for 2003 through 2008 for Cardiovascular, Analgesic, Anti-Infective, Central Nervous System (CNS), Gastrointestinal, Respiratory & Anti-Allergic, Cancer and Others
    • Table 94: Pharmaceutical Research and Development Expenditure by Country in Western Europe: Percentage Market Share for 2003, 2004 and 2005 for France, Germany, UK, Switzerland, Belgium, and others
    • Table 95: Western European Market for Generic Drugs by Country: Annual Sales Estimates in US$ Million for 2003 through 2008 for France, Germany, UK, Spain, and Italy
    • Table 96: United Kingdom Pharmaceuticals Market (2003-2005): Exports and Imports in Million
    • Table 97: Over-the Counter Volume Sales of Drugs by Category in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Units for Gastro/ Intestinal, Cold/Cough, Eye Care/Hayfever, Oral/ Topical Analgesics, FAD/Topical Antiseptics and Other Defined Healthcare
    • Table 98: Over-the Counter Volume Sales of Drugs by Category in the UK: Percentage Market Share for 2004 and 2008 (E) for Gastro/ Intestinal, Cold/Cough, Eye Care/Hayfever, Oral/Topical Analgesics, FAD/Topical Antiseptics and Other Defined Healthcare
    • Table 99: Over-The-Counter Medication Value Sales in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Pounds Sterling for Pain Relief, Skin Treatments, Cough/Cold/Sore Throat, Gastro-Intestinal, Vitamins & Minerals, Medicated Mouthwash/ Sprays, Hayfever Remedies, Eye Care Treatment and Sleeping Aids
    • Table 100: Over-The-Counter Medication Value Sales in the UK: Percentage Market Share for 2004 and 2008 for Pain Relief, Skin Treatments, Cough/Cold/Sore Throat, Gastro-Intestinal, Vitamins & Minerals, Medicated Mouthwash/Sprays, Hayfever Remedies, Eye Care Treatment and Sleeping Aids
    • Table 101: Analgesics Value Sales through Drug Stores in the UK: Annual Market Estimates for 2003 through 2008 in Millions of Pounds Sterling for Adult Oral Analgesics, Pediatric Analgesics, and Topical Analgesics
    • Table 102: Leading Statin Drugs Average New Prescriptions in the UK: 2004 2005 Percentage Market Share for Lipitor, Zocor, Pravachol, Baycol, Lescol, and Mevacor
    • Table 103: Asian Pharmaceuticals Market (2005): Percentage Breakdown of Value Sales by Geographic Region/Country - Japan, China, Australia, South Korea, and Rest of Asia-Pacific
    • Table 104: Chinese Pharmaceuticals Market: Annual Sales in US$ Billion for 2003 through 2005
    • Table 105: Chinese Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008
    • Table 106: Pharmaceuticals Industry Revenue by Province in China: Percentage Market Share for 2005 for Guangdong Province, Shanghai City, and Others
    • Table 107: Demographic Trends in China (2005-2010)
    • Table 108: Indo-US Macro Market Facts
    • Table 109: Generic Opportunities in the US and Indian Presence: 2005-2006
    • Table 110: Generic Opportunities in the US and Indian Presence: 2007
    • Table 111: Generic Opportunities in the US and Indian Presence: 2008
    • Table 112: Alliances between Select Indo-US Generic Players
    • Table 113: ANDA Filings by Indian Companies Exponential Growth & Potential
    • Table 114: India Only Second to the US in DMF Filings: 2003-2004
    • Table 115: Contracted Pharmaceutical and Biotechnology Clinical Research, Chemical Synthesis, and Analysis Services Market for India
    • Table 116: Indian Market for Generic Drugs: Annual Sales Estimates in US$ Million for bears 2003 through 2008
    • Table 117: Indian Chemical Industry Output for Pharmaceuticals: Annual Market Estimates for 2003 through 2008 in Billions of US$
    • Table 118: Pharmaceutical Sales in India: Annual Market Estimates for 2003 through 2008 in Billions of Indian Rupees
    • Table 119: Largest Indian Companies By Market Capitalization (As Of October 2005)
    • Table 120: R&D Spend by Major Indian Pharmaceutical Companies - A Comparison from 2004 through 2008 (In US$ Million)
    • Table 121: Leading Indian Companies - FDA Approved Facilities
    • Table 122: DMF Filings By Leading Indian Companies: 2004
    • Table 123: Pharmaceuticals Value Shipments in Brazil: Annual Market Estimates for 2003 through 2008 in Billions of US$
    • Table 124: Brazilian Market for Generic Drugs: Annual Sales Estimates in US$ Million for Years 2003 through 2008
    • Table 125: Leading Players in Brazilian Generic Drugs Market (2004 & 2005): Percentage Breakdown of Volume Sales for Medley, EMS Sigma Pharma, Biosintetica, Eurofarma, Ranbaxy, Apotex, Merck, Novartis, and Others

Click here to view the full TOC

+44 20 8816 8548

Ask a question about Pharmaceuticals

Enter the characters you see in the picture below
Captcha